Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free ALLO Stock Alerts

Allogene Therapeutics (ALLO) Competitors

Allogene Therapeutics logo
$2.02 -0.07 (-3.35%)
As of 08/28/2026 04:00 PM Eastern
Compare

ALLO vs. NRIX, BEAM, RARE, SLS, and COAG

Should you buy Allogene Therapeutics stock or one of its competitors? Allogene Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), Ultragenyx Pharmaceutical (RARE), SELLAS Life Sciences Group (SLS), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allogene Therapeutics compare to Nurix Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Allogene Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Allogene Therapeutics' return on equity of -50.04% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allogene TherapeuticsN/A -50.04% -36.74%
Nurix Therapeutics -928.44%-76.09%-57.31%

In the previous week, Allogene Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Allogene Therapeutics and 11 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.43 beat Allogene Therapeutics' score of 0.96 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allogene Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nurix Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Allogene Therapeutics currently has a consensus target price of $8.30, indicating a potential upside of 310.89%. Nurix Therapeutics has a consensus target price of $34.21, indicating a potential upside of 30.54%. Given Allogene Therapeutics' higher probable upside, research analysts clearly believe Allogene Therapeutics is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

Allogene Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Allogene Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene Therapeutics$20K34,894.49-$190.89M-$0.67N/A
Nurix Therapeutics$83.98M32.39-$264.46M-$3.45N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Allogene Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$139.74M21.67-$79.99M-$0.86N/A
Allogene Therapeutics$20K34,894.49-$190.89M-$0.67N/A

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-54.75% -30.71% -24.07%
Allogene Therapeutics N/A -50.04%-36.74%

In the previous week, Beam Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for Beam Therapeutics and 12 mentions for Allogene Therapeutics. Beam Therapeutics' average media sentiment score of 1.02 beat Allogene Therapeutics' score of 0.96 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics presently has a consensus price target of $49.00, suggesting a potential upside of 67.12%. Allogene Therapeutics has a consensus price target of $8.30, suggesting a potential upside of 310.89%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

Summary

Beam Therapeutics beats Allogene Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Ultragenyx Pharmaceutical?

Allogene Therapeutics (NASDAQ:ALLO) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Allogene Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 310.89%. Ultragenyx Pharmaceutical has a consensus price target of $59.44, suggesting a potential upside of 132.11%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
Ultragenyx Pharmaceutical
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.84

Allogene Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Allogene Therapeutics' return on equity of -50.04% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Allogene TherapeuticsN/A -50.04% -36.74%
Ultragenyx Pharmaceutical -81.79%-1,024.42%-44.40%

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Allogene Therapeutics. MarketBeat recorded 19 mentions for Ultragenyx Pharmaceutical and 12 mentions for Allogene Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.07 beat Allogene Therapeutics' score of 0.96 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allogene Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
10 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Allogene Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Allogene Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene Therapeutics$20K34,894.49-$190.89M-$0.67N/A
Ultragenyx Pharmaceutical$673M3.75-$575M-$5.84N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 24.30%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 310.89%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

SELLAS Life Sciences Group's return on equity of -35.91% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -35.91% -33.34%
Allogene Therapeutics N/A -50.04%-36.74%

In the previous week, Allogene Therapeutics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 12 mentions for Allogene Therapeutics and 10 mentions for SELLAS Life Sciences Group. Allogene Therapeutics' average media sentiment score of 0.96 beat SELLAS Life Sciences Group's score of 0.62 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Allogene Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Allogene Therapeutics$20K34,894.49-$190.89M-$0.67N/A

Summary

Allogene Therapeutics beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks.

How does Allogene Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

83.6% of Allogene Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hemab Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/A-$24.78N/A
Allogene Therapeutics$20K34,894.49-$190.89M-$0.67N/A

Hemab Therapeutics presently has a consensus target price of $51.40, indicating a potential upside of 14.63%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 310.89%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

In the previous week, Allogene Therapeutics had 10 more articles in the media than Hemab Therapeutics. MarketBeat recorded 12 mentions for Allogene Therapeutics and 2 mentions for Hemab Therapeutics. Allogene Therapeutics' average media sentiment score of 0.96 beat Hemab Therapeutics' score of 0.58 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemab Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hemab Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Allogene Therapeutics N/A -50.04%-36.74%

Summary

Allogene Therapeutics beats Hemab Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALLO vs. The Competition

Export
MetricAllogene TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$722.08M$4.02B$7.24B$12.93B
Dividend YieldN/A3.60%2.54%10.96%
P/E Ratio-3.0111.56271.5025.38
Price / Sales34,894.491,345.97624.0096.54
Price / CashN/A110.5979.2954.21
Price / Book1.6016.5012.956.14
Net Income-$190.89M-$22.76M$3.46B$347.93M
7 Day Performance-3.35%-0.23%-0.11%-0.78%
1 Month Performance11.60%11.93%8.32%5.60%
1 Year Performance78.76%55.61%24.64%15.64%

Allogene Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALLO
Allogene Therapeutics
2.2883 of 5 stars		$2.02
-3.3%		$8.30
+310.9%		+71.2%$722.08M$20KN/A310
NRIX
Nurix Therapeutics
3.4075 of 5 stars		$27.17
+0.4%		$34.21
+25.9%		+178.5%$2.81B$36.77MN/A300
BEAM
Beam Therapeutics
2.0965 of 5 stars		$27.10
+1.3%		$49.00
+80.8%		+74.0%$2.76B$156.04MN/A510
RARE
Ultragenyx Pharmaceutical
3.5456 of 5 stars		$26.13
-1.4%		$57.82
+121.3%		-15.5%$2.61B$673MN/A1,371
SLS
SELLAS Life Sciences Group
0.3284 of 5 stars		$13.00
+1.7%		$10.00
-23.1%		+588.0%$2.58BN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 8/29/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel